These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23437548)

  • 1. [Challenge clinical trial for evaluation of a vaccine candidate strain against cholera].
    Díaz Jidy M; Pérez Rodríguez A; Fernández Llanes R; Bravo Fariñas L; García Sánchez H; Valera Fernández R; García Imia L; Fando Calzada R; Menéndez Hernández J
    Rev Cubana Med Trop; 2010; 62(3):194-9. PubMed ID: 23437548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate.
    Levine MM; Black RE; Clements ML; Young CR; Lanata C; Sears S; Honda T; Finkelstein R
    Dev Biol Stand; 1983; 53():59-65. PubMed ID: 6873477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
    Taylor DN; Tacket CO; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro JP; Kaper JB; Wasserman SS; Edelman R; Levine MM; Cryz SJ
    Infect Immun; 1997 Sep; 65(9):3852-6. PubMed ID: 9284163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh.
    Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Alam MS; Zaman K; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA;
    J Infect Dis; 2005 Aug; 192(4):573-9. PubMed ID: 16028125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
    Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
    Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
    Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
    Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of an engineered bivalent vaccine strain consisting of Vibrio cholerae CT-B and LPS-O antigens.
    Yu X; Ma Q
    Chin J Biotechnol; 1994; 10(4):225-32. PubMed ID: 7780018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.
    Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP
    Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The excretion pattern and protective capacity in rabbits orally immunized with attenuated strains of Vibrio cholerae O1 biotype El Tor].
    García Sánchez HM; García Imia L; Oliva Hernández R; Pérez Quiñoy JL; Cedré Marrero B; Domínguez Iriarte R; Benítez Robles J
    Rev Cubana Med Trop; 1998; 50(2):115-9. PubMed ID: 10349429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638.
    Talavera A; Año G; García H; Moreira T; Delgado H; Riverón L; Gil S; Miranda A; Cedré B; Valmaseda T; Pino Y; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 May; 24(18):3746-9. PubMed ID: 16085342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a live oral cholera vaccine in human volunteers.
    Woodward WE; Gilman RH; Hornick RB; Libonati JP; Cash RA
    Dev Biol Stand; 1976; 33():108-12. PubMed ID: 782960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current status of cholera vaccine development and experience with cholera vaccine trials in volunteers.
    Levine MM; Kaper JB; Herrington D; Losonsky G; Tacket C; Tall B
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):401-15. PubMed ID: 3217822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Kaper JB; Levine MM
    J Infect Dis; 1992 Oct; 166(4):837-41. PubMed ID: 1527420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.